Effect of the thyroid transcription factor 1 expression and treatment discontinuation due to adverse events on progression-free survival in patients with advanced non-squamous non-small cell lung cancer treated with pembrolizumab plus pemetrexed and platinum chemotherapy: a Japanese four-hospital, retrospective study-Reference-Cited by-同舟云学术

Effect of the thyroid transcription factor 1 expression and treatment discontinuation due to adverse events on progression-free survival in patients with advanced non-squamous non-small cell lung cancer treated with pembrolizumab plus pemetrexed and platinum chemotherapy: a Japanese four-hospital, retrospective study

Published:2024 Issue:8 Volume:14 Page:3852-3858
ISSN:2156-6976
Container-title:American Journal of Cancer Research
language:
Short-container-title:Am J Cancer Res

Author:

Mori Shoma

Publisher

e-Century Publishing Corporation

Reference14 articles.

1. Frost N, Zhamurashvili T, von Laffert M, Klauschen F, Ruwwe-Glösenkamp C, Raspe M, Brunn M, Ochsenreither S, Temmesfeld-Wollbrück B, Suttorp N, Grohé C and Witzenrath M. Pemetrexed-based chemotherapy is inferior to pemetrexed-free regimens in thyroid transcription factor 1 (TTF-1)-negative, EGFR/ALK-negative lung adenocarcinoma: a propensity score matched pairs analysis. Clin Lung Cancer 2020; 21: e607-e621.

2. TTF-1 expression predicts the merit of additional antiangiogenic treatment in non-squamous non-small cell lung cancer;Takeuchi;Anticancer Res,2018

3. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer;Ibusuki;Transl Lung Cancer Res,2022

4. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer;Haratani;JAMA Oncol,2018

5. Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, Morris DG, Heng DYC, Pabani A, Dean M and Navani V. Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw Open 2024; 7: e2352302.